Loading
A phase 2 trial of ivonescimab in lung cancer, run by Guangdong Association of Clinical Trials, now recruiting.
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression is a phase 2, interventional study registered as NCT07412262 by Guangdong Association of Clinical Trials, with a registry enrolment figure of 32 participants, started 2026-08-28 and due to reach its primary completion in 2028-03-31. Interventions recorded: Chidamide in combination with Ivonescimab. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Progression Free Survival(PFS) per Response Evaluation Criteria in Solid tumors (RECIST) v1.1. Lung eligibility wording from the registry: "Have histologically or cytologically confirmed locally advanced (IIIB/IIIC stage), metastatic or recurrent (IV stage) non-small cell lung cancer (NSCLC) that is not operable and not suitable for radical concurrent chemoradiotherapy, as classified by the 9th edition of the TNM staging system of the I". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Ivonescimab, Bispecific antibodies, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/